Hepatitis C-vírussal fertozött cirrhosisos betegek kezelésével nyert hazai real-life tapasztalatok a két pegilált interferonnal

Translated title of the contribution: Treatment of hepatits C virus infected patients with cirrhosis in real-life conditions in Hungary with the two pegylated interferons

Márta Varga, Klára Csefkó, Tivadar Bányai, Tibor Martyin, Piroska Lakatos, István Nagy, Attila Pálvölgyi, Anna Tusnádi, Anna Szabó, Miklós Lesch, Béla Sipos, Annamária Budai, Judit Enyedi, Béla Lombay, László Karádil, Zsuzsanna Váczi, Viktor Jancsik, György Weisz, K. Palatka, István Tornai

Research output: Contribution to journalArticle

Abstract

AIMS - In this trial we have analyzed the data of cirrhotic naiv as well as treatment experienced patients with chronic hepatitis C, treated in the East-Hungarian hepatology centers, between 2004 and 2010, because in the era of triple combinations, we mostly treat cirrhotic patients.

PATIENTS AND METHODS - We have found 272 patients and in most of them the cirrhosis was proven by biopsy. These patients were treated with pegylated interferon (pegIFN) alpha plus ribavirin in combination, 172 were naiv and 100 patients were treatment experienced. Data were collected retrospectively and the pretreatment parameters like age, sex, body weight, transaminase level, genotype, initial viral load, comorbidities, and proportion of first and repeated treatments have been analyzed. We have investigated the influence of the initial parameters as well as the type of pegIFN on the complete early virologic response (cEVR) and on the sustained virological response (SVR).

RESULTS - The cEVR was 27% (74/272) and the SVR was 21% (58/272) in the whole patient population. With pegIFN α- 2a, 32% (45/141) cEVR and 28% (39/141) SVR, whereas with pegIFN α-2b 22% (29/131) cEVR and 15% (19/131) SVR were achieved. Among this patient population the largest subgroup was the naiv patients with high viral load (HVL). In this subgroup the SVR was 21% (28/132). However, with pegIFN α-2a SVR was 29% (21/73), whereas with pegIFN α-2b SVR was only 12% (7/59). The above differences found between the two pegIFNs proved to be statistically significant. Age

CONCLUSION - According to these results, cirrhotic patients with hepatitis C may benefit if pegIFN α-2a is used as backbone therapy in triple combinations.

Original languageHungarian
Pages (from-to)569-576
Number of pages8
JournalLege Artis Medicinae
Volume24
Issue number12
Publication statusPublished - 2014

Fingerprint

Hungary
Interferons
Fibrosis
Viruses
Therapeutics
Viral Load
Ribavirin
Chronic Hepatitis C
Gastroenterology
Hepatitis C
Transaminases
Interferon-alpha
Population
Comorbidity
Genotype
Body Weight
Biopsy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Varga, M., Csefkó, K., Bányai, T., Martyin, T., Lakatos, P., Nagy, I., ... Tornai, I. (2014). Hepatitis C-vírussal fertozött cirrhosisos betegek kezelésével nyert hazai real-life tapasztalatok a két pegilált interferonnal. Lege Artis Medicinae, 24(12), 569-576.

Hepatitis C-vírussal fertozött cirrhosisos betegek kezelésével nyert hazai real-life tapasztalatok a két pegilált interferonnal. / Varga, Márta; Csefkó, Klára; Bányai, Tivadar; Martyin, Tibor; Lakatos, Piroska; Nagy, István; Pálvölgyi, Attila; Tusnádi, Anna; Szabó, Anna; Lesch, Miklós; Sipos, Béla; Budai, Annamária; Enyedi, Judit; Lombay, Béla; Karádil, László; Váczi, Zsuzsanna; Jancsik, Viktor; Weisz, György; Palatka, K.; Tornai, István.

In: Lege Artis Medicinae, Vol. 24, No. 12, 2014, p. 569-576.

Research output: Contribution to journalArticle

Varga, M, Csefkó, K, Bányai, T, Martyin, T, Lakatos, P, Nagy, I, Pálvölgyi, A, Tusnádi, A, Szabó, A, Lesch, M, Sipos, B, Budai, A, Enyedi, J, Lombay, B, Karádil, L, Váczi, Z, Jancsik, V, Weisz, G, Palatka, K & Tornai, I 2014, 'Hepatitis C-vírussal fertozött cirrhosisos betegek kezelésével nyert hazai real-life tapasztalatok a két pegilált interferonnal', Lege Artis Medicinae, vol. 24, no. 12, pp. 569-576.
Varga, Márta ; Csefkó, Klára ; Bányai, Tivadar ; Martyin, Tibor ; Lakatos, Piroska ; Nagy, István ; Pálvölgyi, Attila ; Tusnádi, Anna ; Szabó, Anna ; Lesch, Miklós ; Sipos, Béla ; Budai, Annamária ; Enyedi, Judit ; Lombay, Béla ; Karádil, László ; Váczi, Zsuzsanna ; Jancsik, Viktor ; Weisz, György ; Palatka, K. ; Tornai, István. / Hepatitis C-vírussal fertozött cirrhosisos betegek kezelésével nyert hazai real-life tapasztalatok a két pegilált interferonnal. In: Lege Artis Medicinae. 2014 ; Vol. 24, No. 12. pp. 569-576.
@article{32691eedc32b402793a8fb34e9b91b39,
title = "Hepatitis C-v{\'i}russal fertoz{\"o}tt cirrhosisos betegek kezel{\'e}s{\'e}vel nyert hazai real-life tapasztalatok a k{\'e}t pegil{\'a}lt interferonnal",
abstract = "AIMS - In this trial we have analyzed the data of cirrhotic naiv as well as treatment experienced patients with chronic hepatitis C, treated in the East-Hungarian hepatology centers, between 2004 and 2010, because in the era of triple combinations, we mostly treat cirrhotic patients.PATIENTS AND METHODS - We have found 272 patients and in most of them the cirrhosis was proven by biopsy. These patients were treated with pegylated interferon (pegIFN) alpha plus ribavirin in combination, 172 were naiv and 100 patients were treatment experienced. Data were collected retrospectively and the pretreatment parameters like age, sex, body weight, transaminase level, genotype, initial viral load, comorbidities, and proportion of first and repeated treatments have been analyzed. We have investigated the influence of the initial parameters as well as the type of pegIFN on the complete early virologic response (cEVR) and on the sustained virological response (SVR).RESULTS - The cEVR was 27{\%} (74/272) and the SVR was 21{\%} (58/272) in the whole patient population. With pegIFN α- 2a, 32{\%} (45/141) cEVR and 28{\%} (39/141) SVR, whereas with pegIFN α-2b 22{\%} (29/131) cEVR and 15{\%} (19/131) SVR were achieved. Among this patient population the largest subgroup was the naiv patients with high viral load (HVL). In this subgroup the SVR was 21{\%} (28/132). However, with pegIFN α-2a SVR was 29{\%} (21/73), whereas with pegIFN α-2b SVR was only 12{\%} (7/59). The above differences found between the two pegIFNs proved to be statistically significant. Age CONCLUSION - According to these results, cirrhotic patients with hepatitis C may benefit if pegIFN α-2a is used as backbone therapy in triple combinations.",
keywords = "Hepatitis C, Outcome, Pegylated interferon",
author = "M{\'a}rta Varga and Kl{\'a}ra Csefk{\'o} and Tivadar B{\'a}nyai and Tibor Martyin and Piroska Lakatos and Istv{\'a}n Nagy and Attila P{\'a}lv{\"o}lgyi and Anna Tusn{\'a}di and Anna Szab{\'o} and Mikl{\'o}s Lesch and B{\'e}la Sipos and Annam{\'a}ria Budai and Judit Enyedi and B{\'e}la Lombay and L{\'a}szl{\'o} Kar{\'a}dil and Zsuzsanna V{\'a}czi and Viktor Jancsik and Gy{\"o}rgy Weisz and K. Palatka and Istv{\'a}n Tornai",
year = "2014",
language = "Hungarian",
volume = "24",
pages = "569--576",
journal = "Lege Artis Medicinae",
issn = "0866-4811",
publisher = "Literatura Medica Publishing House",
number = "12",

}

TY - JOUR

T1 - Hepatitis C-vírussal fertozött cirrhosisos betegek kezelésével nyert hazai real-life tapasztalatok a két pegilált interferonnal

AU - Varga, Márta

AU - Csefkó, Klára

AU - Bányai, Tivadar

AU - Martyin, Tibor

AU - Lakatos, Piroska

AU - Nagy, István

AU - Pálvölgyi, Attila

AU - Tusnádi, Anna

AU - Szabó, Anna

AU - Lesch, Miklós

AU - Sipos, Béla

AU - Budai, Annamária

AU - Enyedi, Judit

AU - Lombay, Béla

AU - Karádil, László

AU - Váczi, Zsuzsanna

AU - Jancsik, Viktor

AU - Weisz, György

AU - Palatka, K.

AU - Tornai, István

PY - 2014

Y1 - 2014

N2 - AIMS - In this trial we have analyzed the data of cirrhotic naiv as well as treatment experienced patients with chronic hepatitis C, treated in the East-Hungarian hepatology centers, between 2004 and 2010, because in the era of triple combinations, we mostly treat cirrhotic patients.PATIENTS AND METHODS - We have found 272 patients and in most of them the cirrhosis was proven by biopsy. These patients were treated with pegylated interferon (pegIFN) alpha plus ribavirin in combination, 172 were naiv and 100 patients were treatment experienced. Data were collected retrospectively and the pretreatment parameters like age, sex, body weight, transaminase level, genotype, initial viral load, comorbidities, and proportion of first and repeated treatments have been analyzed. We have investigated the influence of the initial parameters as well as the type of pegIFN on the complete early virologic response (cEVR) and on the sustained virological response (SVR).RESULTS - The cEVR was 27% (74/272) and the SVR was 21% (58/272) in the whole patient population. With pegIFN α- 2a, 32% (45/141) cEVR and 28% (39/141) SVR, whereas with pegIFN α-2b 22% (29/131) cEVR and 15% (19/131) SVR were achieved. Among this patient population the largest subgroup was the naiv patients with high viral load (HVL). In this subgroup the SVR was 21% (28/132). However, with pegIFN α-2a SVR was 29% (21/73), whereas with pegIFN α-2b SVR was only 12% (7/59). The above differences found between the two pegIFNs proved to be statistically significant. Age CONCLUSION - According to these results, cirrhotic patients with hepatitis C may benefit if pegIFN α-2a is used as backbone therapy in triple combinations.

AB - AIMS - In this trial we have analyzed the data of cirrhotic naiv as well as treatment experienced patients with chronic hepatitis C, treated in the East-Hungarian hepatology centers, between 2004 and 2010, because in the era of triple combinations, we mostly treat cirrhotic patients.PATIENTS AND METHODS - We have found 272 patients and in most of them the cirrhosis was proven by biopsy. These patients were treated with pegylated interferon (pegIFN) alpha plus ribavirin in combination, 172 were naiv and 100 patients were treatment experienced. Data were collected retrospectively and the pretreatment parameters like age, sex, body weight, transaminase level, genotype, initial viral load, comorbidities, and proportion of first and repeated treatments have been analyzed. We have investigated the influence of the initial parameters as well as the type of pegIFN on the complete early virologic response (cEVR) and on the sustained virological response (SVR).RESULTS - The cEVR was 27% (74/272) and the SVR was 21% (58/272) in the whole patient population. With pegIFN α- 2a, 32% (45/141) cEVR and 28% (39/141) SVR, whereas with pegIFN α-2b 22% (29/131) cEVR and 15% (19/131) SVR were achieved. Among this patient population the largest subgroup was the naiv patients with high viral load (HVL). In this subgroup the SVR was 21% (28/132). However, with pegIFN α-2a SVR was 29% (21/73), whereas with pegIFN α-2b SVR was only 12% (7/59). The above differences found between the two pegIFNs proved to be statistically significant. Age CONCLUSION - According to these results, cirrhotic patients with hepatitis C may benefit if pegIFN α-2a is used as backbone therapy in triple combinations.

KW - Hepatitis C

KW - Outcome

KW - Pegylated interferon

UR - http://www.scopus.com/inward/record.url?scp=84920458727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920458727&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84920458727

VL - 24

SP - 569

EP - 576

JO - Lege Artis Medicinae

JF - Lege Artis Medicinae

SN - 0866-4811

IS - 12

ER -